 Clinical testing is currently under way to determine whether NK cell activity augmentation by rintatolimod in vivo associates with lessened CFS disease severity and increased physical endurance and performance measures.Twice, in 1998 and 2000, Hemispherx received notices of violation from the FDA for promoting rintatolimod as safe and effective before FDA approval, in violation of the Federal Food, Drug, and Cosmetic Act.Also in the late 1990s, Manuel Asensio, reported on Hemispherx, saying the company was overvalued.